Skip to main content

Table 1 Differential gene expression between metastatic melanoma and non-metastatic cutaneous tumors

From: The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis

Gene symbol Increase in metastatic melanoma relative to Gene symbol Decrease in metastatic melanoma relative to
  MIS/Thin BCC/SCC/MIS/Thin   MIS/Thin BCC/SCC/MIS/Thin
MAGEA3/A6/A12 125/119/57 27/25/29 CALML5 193 228
MAGEA1/A2/A5 24/57/10 13/31/6 DSC1/3 186/64 198/71
CSAG2 76 36 PKP1 166 240
TRIM51 51 35 CLCA2 162 177
GDF15 30 47 DSG1/3 160/73 178/119
GYPC 18 14 LY6D 143 147
SPP1 15 7 SERPINB3/B5/B7 111/199/106 184/227/144
KIFC1 15 3 C19orf33 122 135
RGS20 14 14 FLG 112 112
C1orf90 13 15 KRT5/16/17 49/111/105 62/196/274
BCL2A1 12 12 KLK7/8/10/11 99/23/27/65 112/32/81/83
SOX5 15 8 LOR 95 98
SLC16A4 12 29 LGALS7 84 89
AKT3 11 9 CST6 82 56
PEG10 11 10 TRIM29 79 119
BUB1 14 3 SFN 77 125
RASGRF1 8 12 ASAH3 69 56
MMP14 8 6 GATA3 63 54
SPRED1 6 4 CBLC 60 64
GPR19 6 5 RAB25 59 78
CDK2 6 7 S100A14/A7/A7L1 27/57/21 44/60/82
HOXA10 3 4 ICEBERG 52 48
HOXB6/7/9 4/5/3 6/7/3 IVL 50 76
HEY1 7 16 ELOVL4 38 34
DUSP4 8 10 CXCL14 36 37
DUSP6 8 6 FOXN1 33 34
CDC45L 7 8 AQP3 29 31
CDC6 9 4 TP73L 29 48
RRM2 6 4 MUC15 25 21
TYMS 4 3 RORA 24 22
BIRC5 4 2 CD24 19 38
  1. The initial statistical analysis addressed the question of whether there were genes differentially expressed (increased or decreased) between primary cancers (BCC/SCC/PCM) and metastatic cancers (metastatic melanoma). Column 1 (MIS/thin) are comprised of only such lesions, while column 2 (BCC/SCC/MIS/Thin) is comprised of all 4 histologic subtypes. All of the annotated genes listed above had a > 2-fold up- or down-regulation in gene expression with the full names of each gene, accession number and gene identification provided in supplementary table 1. Abbreviations: MIS, melanoma-in-situ, BCC, basal cell carcinoma, SCC, squamous cell carcinoma, Thin, thin melanomas < 1.5 mm in Breslow's thickness.